Current preclinical research is investigating the KLOW multi-peptide formulation across tissue regeneration, connective tissue repair, inflammation modulation, wound healing, musculoskeletal recovery, and regenerative medicine by combining the complementary biological actions of GHK-Cu, BPC-157, KPV, and TB-500
As the drug blocks IL-23 upstream, in a clinical trial PASI 75 was maintained in 42% of participants after 1 year from the last dose of treatment
2022 Apr;22(2):97-105
Gleichzeitig bleibt die wissenschaftliche Datenlage begrenzt
If you're stuck in a frustrating cycle of slow healing, recovering from surgery, or simply want to optimize your body's natural repair abilities, peptide therapy might be the missing piece in your recovery puzzle